Tonozzi Theresa R, Braunstein Glenn D, Kammesheidt Anja, Curran Chris, Golshan Shahrokh, Kelsoe John
Pathway Genomics, San Diego, CA 92121, USA.
Patients Like Me, Cambridge, MA 02142, USA.
Pharmacogenomics. 2018 Oct;19(15):1169-1179. doi: 10.2217/pgs-2018-0088. Epub 2018 Sep 12.
To compare pharmacogenetic test predictions with self-reported treatment experience and side effect tolerability among patients with depression taking psychotherapeutic medications.
Subjects completed a survey recalling medication effectiveness and side effects and then underwent pharmacogenetic testing.
Our 15 gene pharmacogenetic panel predicted efficacy (p < 0.001) but did not predict side effect tolerability (p = 0.70) in a group of 352 patients. The pharmacogenetic panel and reported efficacy corresponded 60% of the time and medication tolerability agreed 71% of the time.
Pharmacogenetic testing may be a useful adjunct to predict efficacy of medications used to treat depression.
比较服用心理治疗药物的抑郁症患者的药物遗传学检测预测结果与自我报告的治疗经历及副作用耐受性。
受试者完成一项回顾药物疗效和副作用的调查，然后接受药物遗传学检测。
在一组352名患者中，我们的15基因药物遗传学检测板预测了疗效（p < 0.001），但未预测副作用耐受性（p = 0.70）。药物遗传学检测板与报告的疗效在60%的时间内相符，药物耐受性在71%的时间内一致。
药物遗传学检测可能是预测用于治疗抑郁症药物疗效的有用辅助手段。
